The global botulinum
toxin (BNT) market is expected to reach a value of USD 7.3 billion by
2025. The constant introduction of innovative products for enhancement of aesthetic
appeal supporting minimally invasive aesthetic treatments is the prime factor
driving the growth of the market.
In addition, rapid growth of the sector is attributed to the
rising demand for minimally invasive or non-invasive procedures. These procedures
provide advantages such as small incision, shorter hospital stay and rapid
wound healing, and hence lead to larger acceptance and demand. In addition,
availability of wide variety of minimally invasive or non-invasive treatment
options is pushing the global botulinum toxin market towards growth.
Also, the successful completion of research projects is
expected to expand the applications of presently approved products. Companies
are trying to widen the application of botulinum toxin in therapeutic area
through various research activities. For instance, Botox by Allergan received
the U.S. FDA approval for the treatment of strabismus (crossed eyes) and
blepharospasm associated with dystonia in 1989. Furthermore, in 2004, Botox was
approved by the U.S. FDA for hyperidrosis, cervical dystonia, upper limb
spasticity, chronic migraine and urinary incontinence in 2009, 2010 and 2011
respectively. Hence, these factors all together will aid in boosting the growth
of BNT sales during the forecast period.
Browse full research report on Botulinum Toxin Market: http://www.grandviewresearch.com/industry-analysis/botulinum-toxin-market
Further Key Findings from the Study Suggest:
- The
rapid adoption of minimally invasive treatment is augmenting the growth of
neurotoxins market.
- The
botulinum toxin type A segment accounted for the largest share in 2015 and
is also anticipated to be the fastest growing segment during the forecast
period
- In
2015, North America dominated the global space with the largest revenue
share owing to high demand for minimally invasive or non-invasive
aesthetic treatments
- Asia
Pacific is expected to emerge as the fastest growing region during the
forecast period, mainly due to growing social awareness regarding
anti-wrinkle procedures in India, China, and Japan
- Major
players competing in this market include but are not limited to Allergan,
Inc.; Ipsen Group; Merz GmbH and Co. KGaA, Medytox,Inc.; US Worldmed, LLC;
Lanzhou Institute of Biological Products. Co.Ltd. and Revance
Therapeutics, Inc.
Grand View Research has segmented the botulinum toxin market
by type, end use, and region:
Product Type Outlook (Revenue, USD Million; 2013 - 2025)
- Botulinum
Toxin Type A
- Botulinum
Toxin Type B
End Use Outlook (Revenue, USD Million; 2013 - 2025)
- Therapeutic
- Aesthetic
Regional Outlook (Revenue, USD Million; 2013 - 2025)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia
Pacific
- China
- Japan
- Latin
America
- Mexico
- Brazil
- MEA
- South
Africa
About Grand View Research
Grand View Research, Inc. is a U.S. based market research
and consulting company, registered in the State of California and headquartered
in San Francisco. The company provides syndicated research reports,
customized research reports, and consulting services. To help clients make
informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
For more information:
http://www.grandviewresearch.com
No comments:
Post a Comment